Our pipeline consists of highly differentiated molecules that were designed and optimized to effectively block key oncogenic pathways in hematological malignancies and solid tumors to address important unmet needs in patients with cancer.

We have developed a diverse pipeline consisting of four distinct programs that utilized three unique small molecule modalities, enzyme inhibition, disruption of protein-protein interactions, and targeted protein degradation. 

Our differentiation strategy is to design and optimize each of our small molecule therapeutics to possess specific properties that have the potential to benefit patients:

  • PRT3789 (SMARCA2), we sought high selectivity over SMARCA4 to elicit synthetic lethality using a targeted protein degrader approach
  • For PRT2527 (CDK9), we optimized for superior selectivity over previously developed CDK9i to improve tolerability
ProgramCancer IndicationsDiscoveryPhase 1Phase 2/3Strategic Priorities
PR-01
SMARCA2
PRT3789 (IV)
Patients with SMARCA4 mutated NSCLC and other cancers
 
Drive to POC in 2024
CDK9
PRT2527
Patients with B, T-cell malignancies and AML 
 
Drive to POC in 2024
SMARCA2
(Oral)
Patients with SMARCA4 mutated NSCLC and other cancers
 
Target IND 1H 2024
SMARCA*
Precision ADC
Solid Tumors & Heme Malignancies not addressed by selective SMARCA2 degraders
 
Advance a Precision ADC Program with SMARCA Payload
New precision ADCs*
Solid Tumors
Heme Malignancies
 
Continue to build Precision ADC platform with novel payloads
Small Molecule Discovery
Solid Tumors
Heme Malignancies
 
Advance a first-in-class small molecule program for a biomarker selected cancer
PR-01
SMARCA2
PRT3789 (IV)
Patients with SMARCA4 mutated NSCLC and other cancers

Discovery

Phase 1

Phase 2

 
Areas of Focus: Drive to POC in 2024
CDK9
PRT2527
Patients with B, T-cell malignancies and AML 

Discovery

Phase 1

Phase 2

 
Areas of Focus: Drive to POC in 2024
SMARCA2
(Oral)
Patients with SMARCA4 mutated NSCLC and other cancers

Discovery

Phase 1

Phase 2

 
Areas of Focus: Target IND 1H 2024
SMARCA*
Precision ADC
Solid Tumors & Heme Malignancies not addressed by selective SMARCA2 degraders

Discovery

Phase 1

Phase 2

 
Areas of Focus: Advance a Precision ADC Program with SMARCA Payload
New precision ADCs*
Solid Tumors
Heme Malignancies

Discovery

Phase 1

Phase 2

 
Areas of Focus: Continue to build Precision ADC platform with novel payloads
Small Molecule Discovery
Solid Tumors
Heme Malignancies

Discovery

Phase 1

Phase 2

 
Areas of Focus: Advance a first-in-class small molecule program for a biomarker selected cancer

*In partnership with